Novastra Therapeutics Will Present OAP-101 Data
Initial clinical results for the cancer candidate will be revealed at the ESMO Congress on October 24, 2026.
Updated on Oct. 13, 2026 in Cancer
Live Poll
Should companies present preliminary clinical data for new cancer therapies before final study results exist?
Novastra Therapeutics will present early clinical data for its OAP-101 candidate on October 24, 2026, at the ESMO Congress in Madrid. The presentation will feature results from an investigator-initiated Phase 1 study focused on patients with advanced metastatic melanoma.
Why it matters
The OAP-101 candidate uses a supramolecular nanocloak to activate the cGAS-STING pathway, a strategy designed to help overcome the resistance of cold solid tumors to existing anti-PD-1 therapies. This study aims to provide new evidence for treating patients who have not responded to current checkpoint inhibition methods.
The clinical results will be shared during poster session 2000P on October 24, 2026, scheduled from 12:00 to 12:45 CEST. The full study abstract is set to be released publicly on October 19, 2026, at 12:05 a.m. CEST.
The players
Novastra Therapeutics
This clinical-stage biotechnology company maintains its headquarters in Cambridge, Massachusetts, and operates an additional hub in Shanghai.
Junling Guo
Junling Guo serves as the Chief Executive Officer of Novastra Therapeutics.
The details
OAP-101 utilizes a specialized nanocloak to encapsulate tumor-cell antigens, facilitating their presentation to the immune system. By combining this delivery method with innate immune stimulation, researchers hope to improve outcomes for cancer patients whose tumors have previously resisted conventional treatments.
Timeline
October 19, 2026: The full study abstract will be released at 12:05 a.m. CEST.
October 23-27, 2026: The ESMO Congress 2026 will be held in Madrid, Spain.
October 24, 2026: Clinical data for OAP-101 will be presented between 12:00 and 12:45 CEST.
The Big Picture
The study marks an attempt to leverage the cGAS-STING pathway to overcome tumor resistance, mirroring a broader industry shift toward innate immune stimulation. This development highlights the ongoing evolution in oncology research as developers seek to move beyond traditional checkpoint inhibitors.
This research trial aims to identify new treatment avenues for patients with metastatic melanoma who have failed to respond to standard anti-PD-1 therapies. While the findings represent early-stage data, they offer potential insight into future therapeutic options for individuals managing treatment-resistant solid tumors.
The takeaway
The upcoming presentation underscores the importance of continued innovation in targeting tumors that remain unresponsive to current medical standards. Interested parties should monitor the release of the abstract on October 19 for early insights into the trial findings.
Further reading
Learn more about the latest research and clinical developments in Cancer.
Live Poll
Should companies present preliminary clinical data for new cancer therapies before final study results exist?
